Kailera Therapeutics is trading at $19.12 (-4.26%) as investors continue to focus on side effects from its oral GLP-1 obesity program.
- The stock remains under pressure following reports that its weight-loss drug showed high rates of nausea and vomiting despite meeting its primary efficacy goals.
- Broader weakness across the biotechnology sector is contributing to the downward momentum in today's session.